-
Uncategorized2 months agoSTAT+: Sanofi MS drug gets positive review in Europe following FDA
Regeneron is in the headlines again: It cut a pricing deal with the Trump administration and won approval for a hearing loss gene therapy. Also, Medicare...
-
Uncategorized2 months ago
BioSpace elevates journalism as biopharma evolves in the Trump era
Neal and Azbee awards have validated our approach to reporting on the industry at a time of unprecedented shifts at the FDA and other federal agencies.
-
Uncategorized2 months ago
Daiichi Sankyo shares slip after delaying annual earnings report
Daiichi Sankyo shares slip after delaying annual earnings report
-
Uncategorized2 months ago
Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer
Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or efficacy concerns.
-
Uncategorized2 months ago
Japanese Pharma Companies Turning to CDMOs Earlier in Product Life Cycle
Japanese pharmaceutical companies are engaging CDMOs earlier in the development cycle, as increasing complexity in peptide programs places greater strain on in-house capabilities, according to officials...
-
Uncategorized2 months agoThis week in Drug Discovery (20 – 24 April)
News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW. This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the...
-
Uncategorized2 months ago
Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection
Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the...
-
Uncategorized2 months ago
Regeneron finally joins Trump’s drug pricing push while notching landmark approval
Of the 17 companies that were implored by the White House last July to apply Most Favored Nation pricing to their drugs, Regeneron is the last...
-
Uncategorized2 months ago
Pfizer’s strategy chief Andrew Baum steps down; Helus Pharma swaps out CEO after two months
→ Ex-Citi analyst Andrew Baum has left his role as chief strategy and innovation officer at Pfizer, but he will be a senior strategic advisor to...
-
Uncategorized2 months ago
Daiichi Sankyo postpones annual results, stock dips
Daiichi Sankyo has pushed back the reporting of its annual results, saying it needs more time to finalize the numbers. The Japanese company had intended to...
Hantavirus One-Shot mRNA Vaccine Fully Protects in Syrian Hamster Model
SonoThera Raises $125M to Develop Ultrasound-Mediated Genetic Medicines
